Novartis to Invest $23 Billion in U.S. Facilities

Novartis announced it will spend $23 billion to construct and expand facilities in the United States. The planned investment includes six new manufacturing plants, including two radioligand therapy manufacturing facilities in Florida and Texas, and a new $1 billion biomedical research hub in San Diego, CA, which is set to open between 2028 and 2029. Radioligand therapy manufacturing facilities in Indiana, New Jersey, and California will also be expanded. The move comes amid Trump administration’s recent announcement that major tariffs will soon be imposed on pharmaceutical imports.